BRIEF-Alnylam Receives Positive CHMP Opinion For Vutrisiran For The Treatment Of Attr Amyloidosis With Cardiomyopathy

Reuters
28 Apr
BRIEF-Alnylam Receives Positive CHMP Opinion For Vutrisiran For The Treatment Of Attr Amyloidosis With Cardiomyopathy

April 28 (Reuters) - Alnylam Pharmaceuticals Inc ALNY.O:

  • ALNYLAM RECEIVES POSITIVE CHMP OPINION FOR VUTRISIRAN FOR THE TREATMENT OF ATTR AMYLOIDOSIS WITH CARDIOMYOPATHY

  • ALNYLAM PHARMACEUTICALS INC - EUROPEAN COMMISSION DECISION ON VUTRISIRAN EXPECTED JUNE 2025

Source text: ID:nBw6nThQwa

Further company coverage: ALNY.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10